![Gianluca Rossetti](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Giuseppe Mazza | M | - |
Engitix Ltd.
![]() Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 8 años |
David Dally | M | - |
Engitix Ltd.
![]() Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 6 años |
Stephen Brindle | M | - |
Engitix Ltd.
![]() Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 8 años |
Sonia Quaratino | M | - |
Engitix Ltd.
![]() Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 1 años |
Massimo Pinzani | M | - |
Engitix Ltd.
![]() Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 8 años |
Mike E. Platt | M | - |
Engitix Ltd.
![]() Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | - |
Eduardo Bravo | M | - |
Engitix Ltd.
![]() Engitix Ltd. Miscellaneous Commercial ServicesCommercial Services Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016. | 4 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Reino Unido | 7 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Gianluca Rossetti
- Red Personal